Updated: January 21, 2021

Joshua Brown, PharmD, PhD, MS

joshua.brown@ufl.edu
T: (352) 294-8593
F: (352) 273-6270

1225 Center Dr. HPNP #3320
PO Box 100496
Gainesville, FL 32610-0496

Biography: Joshua Brown joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2016. He has experience in clinical pharmacy, health economics and outcomes research, and pharmacoepidemiology across academic, pharmaceutical industry, and managed care. His past and ongoing clinical interests have been in the cardiovascular and hematology/oncology therapeutic areas including comparative effectiveness and safety research with a focus on anticoagulation and quality of care in thrombotic conditions such as atrial fibrillation, venous thromboembolism, and cancer. His current research program and collaborations focus on translational research methods for pharmacoepidemiologic and pharmacoeconomic evaluations of generic drugs and biosimilars, generation of real-world evidence for drug-drug interactions, and drug repurposing studies (e.g. aging and Parkinson's Disease). His academic work has been funded by the NIH, FDA, Bill & Melinda Gates Foundation, and the PhRMA Foundation in addition to contracts with pharmaceutical industry. In 2017, Brown was named a Claude D. Pepper Junior Scholar to conduct translational research in geriatric pharmacoepidemiology and healthy aging. Dr. Brown has published over 100 articles and holds several editorial positions with high impact specialty journals. Josh is actively involved in the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoepidemiology (ISPE), and the International Society for Pharmacoeconomic & Outcomes Research scientific societies. Dr. Brown is the academic advisor of the University of Florida student chapter of AMCP and a member of Kappa Psi Pharmaceutical Fraternity, Rho Chi Honors Society, and Phi Lambda Sigma pharmacy leadership society. Dr. Brown was awarded as the AMCP Foundation's "New Practitioner" for his early career contributions to managed care pharmacy and research.

Current Employment

2016 – present **Assistant Professor (tenure track)**
Department of Pharmaceutical Outcomes & Policy
University of Florida College of Pharmacy – Gainesville, FL

2018 – present **Associate Graduate Program Director**
Department of Pharmaceutical Outcomes & Policy
University of Florida College of Pharmacy – Gainesville, FL

Affiliations

2020 – present **Faculty Lead, MEMORY Data Repository**
Consortium for Medical Marijuana Clinical Outcomes Research
University of Florida – Gainesville, FL

2019 – present **Affiliate Faculty** and **Core Leader (Geriatric Pharmacoepidemiology)**
Center for Drug Evaluation & Safety (CoDES)
University of Florida – Gainesville, FL

2018 – present **Affiliate Faculty**
Norman Fixel Institute for Neurological Diseases
University of Florida – Gainesville, FL

Education

2014 – 2016 ***Ph.D. Pharmaceutical Outcomes & Policy***
University of Kentucky College of Pharmacy – Lexington, KY
Dissertation title: "Vena Cava Filter Utilization and Retrieval: A Quality of Care Issue"
Co-chairs: Drs. Jeffery Talbert and Val Adams

2011 – 2014 ***M.S. Pharmaceutical Evaluation & Policy***
University of Arkansas for Medical Science (UAMS)
College of Pharmacy – Little Rock, AR
Thesis title: "Predictive validity of inappropriate prescribing criteria in the elderly"
Chair: Dr. Bradley Martin

2010 – 2014 ***Pharm.D. Doctor of Pharmacy***
UAMS - College of Pharmacy – Little Rock, AR
With honors, With honors in research

2006 – 2010 ***B.S. Biochemistry, Cum laude***
University of Arkansas – Fayetteville, AR

Former Employment

7/2014 – 11/2016 ***Humana-Pfizer Post-Doctoral Fellow***
Comprehensive Health Insights, Humana Inc. – Louisville, KY
Real World Data and Analytics, Outcomes & Evidence, Global Health & Value, Pfizer Inc. – New York, NY
Supervisors: Margaret Pasquale, PhD; Jim Harnett, PharmD, MS; Richard Willke, PhD; Marc Berger, PhD; Phil Schwab, PhD

7/2014 – 11/2016 ***Research Fellow***
Institute for Pharmaceutical Outcomes & Policy – University of Kentucky College of Pharmacy – Lexington, KY
Supervisor: Jeffery Talbert, PhD

Publications (106 in total; 83 as first or senior author)

Research Articles

1. **Brown JD**, Sato R, Morley JE. Effect of inpatient and outpatient pneumonia on mobility disability, gait speed, and physical activity in older adults. *Journal of Clinical Medicine.* 2021, 10(6), 1236; https://doi.org/10.3390/jcm10061236.
2. Li Y, Delcher PC, **Brown JD**, Wei YJ, Reisfield GM, Winterstein AG. Utilization patterns of skeletal muscle relaxants among commercially insured adults in the United States from 2006 to 2018. *Pain Medicine*. 2021 (In press).
3. Dalton R, **Brown JD**, Duarte J. Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines. *Clinical and Translational Science*. 2021 (In press).
4. **Brown JD**, Cicali B, Henriksen C, Malaty I, Okun MS, Armstrong MJ. Comparative pharmacovigilance assessment of mortality in pimavanserin versus treatment alternatives and other antipsychotic medications. *Journal of Managed Care and Specialty Pharmacy*. 2020 (In press).
5. Goodin AJ, **Brown JD**, Roussos-Ross DK, Hincapie Castillo JM. A Survey Assessment of Clinician Perceptions of Opioid Supply and Monitoring Requirement Policy Changes. *Journal of Opioid Management*. 2021 (In press).
6. Farhan N, Cristofoletti R, Basu S, Kim S, Lingienni K, Jiang S, **Brown JD**, Fang L, Lesko L, Schmidt S. Physiologically Based Pharmacokinetics Modeling to Investigate Formulation Factors Influencing the Generic Substitution of Dabigatran Etexilate. *CPT:Pharmacometrics & Systems Pharmacology*. 2021 Jan 15. doi: 10.1002/psp4.12589. PMID 33449439.

7. Spargo A, Yost C, Squires P, Raju A, Schroader B, **Brown JD**. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia. *Journal of Managed Care & Specialty Pharmacy*. 2020 (In press).
8. Goodin AJ, Bai J, Delcher PC, **Brown JD**, Roussos-Ross DK. Obstetrician-Gynecologist Perceptions and Utilization of Prescription Drug Monitoring Programs: A Survey Study. *Medicine*. 2021 Jan 8;100(1):e24268. doi: 10.1097/MD.0000000000024268. PMID: 33429837 PMCID: PMC7793317.
9. Sunaga T, Cicali B, Schmidt S, **Brown JD**. Effect of CYP3A4 inducing drug-drug interactions on contraceptive failures stratified by route of administration. *Contraception*. 2020 Dec 17;S0010-7824(20)30439-X. doi: 10.1016/j.contraception.2020.12.002. PMID:33345974.
10. **Brown JD**, Vouri SM, Manini TM. Survey reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic. *Research in Social and Administrative Pharmacy*. 2020 Nov 12;S1551-7411(20)31190-6. doi: 10.1016/j.sapharm.2020.11.005. PMID:33221267. PMCID:PMC7659512.
11. **Brown JD**, Alipour-Haris G, Pahor M, Manini TM. Association between a deficit accumulation frailty index and mobility outcomes in older adults: Secondary analysis of the Lifestyle Interventions and Independence for Elders (LIFE) Study. *Journal of Clinical Medicine*. 2020. 2020, 9(11), 3757; https://doi.org/10.3390/jcm9113757. PMID:33266358. PMCID:PMC7700674.
12. Lingineni K, Farhan N, Kim S, Gordon LA, Kumar P, Penzak S, Hadigan C, George JM, **Brown JD**, Schmidt S. Quantitative Benefit-Risk Assessment of P-gp Mediated Drug-Drug Interactions (DDIs) of Dabigatran Co-Administered with Pharmacokinetic Enhancers in Patients with Renal Impairment. *Clinical Pharmacology & Therapeutics*. 2020 Oct 19. doi: 10.1002/cpt.2087. PMID:33073366.
13. Tran PT, Slayton WB, Dalal M, **Brown JD**. Incidence and risk factors for 30-day readmission after inpatient chemotherapy among acute lymphoblastic leukemia patients. *Healthcare*. 2020 Oct 14;8(4):401. doi: 10.3390/healthcare8040401. PMID:33066571. PMCID:PMC7720128.
14. Squires P, Pahor M, Manini T, Vouri SM, **Brown JD**. Impact of anticholinergic medication burden on mobility and falls in the Lifestyle Interventions for Elders (LIFE) Study. *Journal of Clinical Medicine*. J. Clin. Med. 2020, 9(9), 2989; https://doi.org/10.3390/jcm9092989. PMID:32947839. PMCID:PMC7564216.
15. Wang CY, Pham PN, Thai TN, Brown JD. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. Pharmacoeconomics. 2020 Dec;38(12):1333-1343. doi: 10.1007/s40273-020-00960-0. Epub 2020 Sep 14. PMID: 32924092.
16. Sarayani A, **Brown JD**, Goodin AJ, Squires P, Pham P, Cicali B, Henriksen C, Schmidt S, Winterstein AG. A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives – A test case for the impact of a known drug-drug interaction. *Epidemiology*. 28 Feb 2021, 32(2):268-276. DOI: 10.1097/ede.0000000000001302 PMID: 33196560 PMCID: PMC7850590.
17. Wang W, Lo Re V, Guo Y, Xiao H, **Brown JD**, Park H. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus infected patients in the U.S. *Alimentary Pharmacology & Therapeutics*. 2020 Nov;52(10):1592-1602. doi: 10.1111/apt.16081. Epub 2020 Sep 15. PMID:32931606.
18. **Brown JD**, Lo-Ciganic W, Shao H, Pahor M, Manini T. Trajectories of Short Physical Performance Battery are strongly associated with future major mobility disability: Results from

the LIFE Study. *Journal of Clinical Medicine*. 2020, 9(8), 2332; https://doi.org/10.3390/jcm9082332. PMID:32707877. PMCID:PMC7465072.

19. Sarayani A, Cicali B, Henriksen CH, **Brown JD**. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. *Research in Social and Administrative Pharmacy*. 2020 Apr 19. doi: 10.1016/j.sapharm.2020.04.016. Online ahead of print. PMID:32327397. PMCID:PMC7166303.
20. **Brown JD**, Costales B, Wegmann SVB, Goodin AJ, Segal R, Winterstein AG. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. *Journal of Clinical Medicine*. 2020 Apr 18;9(4):1166. doi:10.3390/jcm9041166. PMID:32325769. PMCID:PMC7230351.
21. **Brown JD**, Wang CY, Pahor M, Manini T. Three-year post-intervention follow-up comparison of healthcare resource utilization and costs in the Lifestyle Interventions and Independence for Elders (LIFE) Study. *Journals of Gerontology: Medical Sciences*. 2020 Apr 9. doi:10.1093/gerona/glaa088. PMID:32270182.
22. **Brown JD**, Delcher PC, Bae J, Roussos-Ross D, Goodin AJ. OB/GYN Perceptions of Prescription Drug Monitoring Programs as a Primary Prevention Tool for Neonatal Abstinence Syndrome. *Research in Social and Administrative Pharmacy*. 2020 Mar 31:S1551-7411(19)31166-0. doi: 10.1016/j.sapharm.2020.03.010. Epub ahead of print. PMID: 32265114.
23. Rhew K, **Brown JD**, Oh JM. Atopic disease and anemia in Korean patients: cross-sectional study with propensity score analysis. *International Journal of Environmental Research and Public Health.* 2020 Mar 18;17(6):1978. doi: 10.3390/ijerph17061978. PMID: 32197291; PMCID: PMC7142528.
24. Pham PN, Lesko L, Schmidt S, Lip GYH, **Brown JD**. Association of Oral Anticoagulants and Verapamil or Diltiazem with adverse bleeding events in patients with non-valvular atrial fibrillation and normal renal function. *JAMA Network Open*. 2020 Apr 1;3(4):e203593. doi: 10.1001/jamanetworkopen.2020.3593. PMID: 32329770; PMCID: PMC7182798.
25. Shah C, **Brown JD**. Reliability and Validity of the Short Form 12 Item Version 2 (SF-12v2) Health-Related Quality of Life Survey and Disutilities Associated With Relevant Conditions in the U.S. Older Adult Population. *Journal of Clinical Medicine*. 2020 Feb 29;9(3):661. doi: 10.3390/jcm9030661. PMID: 32121371; PMCID: PMC7141358.
26. Li Y, Delcher PC, **Brown JD**, Wei YJ, Reisfield GM, Winterstein AG. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. *Clinical Pharmacology & Therapeutics*. 2020 Feb 5. doi: 10.1002/cpt.1807. Epub ahead of print. PMID: 32022906.
27. Zhou Z, Bhattacharjee S, Kwoh CK, Tighe PJ, Malone DC, Slack M, Wilson DL, **Brown JD**, Lo-Ciganic WH. Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016. *Journal of Clinical Medicine*. 2019 Dec 29;9(1):83. doi: 10.3390/jcm9010083. PMID: 31905718; PMCID: PMC7019734.
28. Hayes CJ, Krebs E, Hudson T, **Brown JD**, Martin BC. Impact of Opioid Dose Escalation on the Development of Substance Use Disorders, Accidents, Self-Inflicted Injuries, Opioid Overdoses, and Alcohol and Non-Opioid Drug-Related Overdoses: A Retrospective Cohort Study. *Addiction*. 2020 Jun;115(6):1098-1112. doi: 10.1111/add.14940. Epub 2020 Jan 15. PMID: 31944486.
29. Hayes CJ, Krebs E, Hudson T, **Brown JD**, Martin BC. Impact of Opioid Dose Escalation on Pain Intensity: A Retrospective Cohort Study. *Pain*. 2020 May;161(5):979-988. doi: 10.1097/j.pain.0000000000001784. PMID: 31917775.

30. Cheng Y, Goodin AJ, Pahor M, Manini T, **Brown JD**. Healthcare utilization and physical functioning in older adults in the United States. *Journal of the American Geriatrics Society*. 2020 Feb;68(2):266-271. doi: 10.1111/jgs.16260. Epub 2019 Nov 22. PMID: 31755551.
31. Talevi A, Morales JF, Podichetty J, Kim S, Hather G, Bloomingdale PC, Burton J, **Brown JD**, Winterstein AG, Schmidt S, White K, Conrado DJ. Machine Learning in Drug Discovery and Development Part 1 – A Tutorial. *CPT:Pharmacometrics and Systems Pharmacology*. 2020 Mar;9(3):129-142. doi: 10.1002/psp4.12491. Epub 2020 Mar 11. PMID: 31905263; PMCID: PMC7080529.
32. Wang CY, Kim S, Lingeneni K, Schmidt S, Diaby V, **Brown JD**. Predicting Cost-Effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates among Patients with Atrial Fibrillation. *Clinical and Translational Science*. 2020 Mar;13(2):352-361. doi: 10.1111/cts.12719. Epub 2020 Feb 13. PMID: 32053288; PMCID: PMC7070788.
33. Brown P, RELISH Consortium [**Brown JD**, Goodin AJ], Zhou Y. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database*. 2019,baz085, 1-67. doi: 10.1093/database/baz085.
34. Wang CY, **Brown JD**. Readmissions after Pancreatic Surgery in Patients with Pancreatic Cancer: Does hospital variation exist for quality measurement? *Visceral Medicine.* 2019. DOI: 10.1159/000502894.
35. Patel K, **Brown JD**. Disparities in the Use of Cardiac Rehabilitations after a Myocardial Infarction in the United States. *Journal of Clinical Medicine*. 2019 Jul 10;8(7):1006. doi: 10.3390/jcm8071006. PMID: 31295853; PMCID: PMC6678860.
36. Olasupo O, Segal R, **Brown JD**. Missed Opportunities for Pneumococcal Vaccinations in High-Risk and Older Adults in the United States. *Journal of Infection and Public Health*. 2020 Jan;13(1):101-103. doi: 10.1016/j.jiph.2019.06.010. Epub 2019 Jul 3. PMID: 31279802.
37. Squires PJ, Pahor M, Manini T, **Brown JD**. Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders (LIFE) Study. *Pharmacotherapy.* 2019 Aug;39(8):816-826. doi: 10.1002/phar.2299. Epub 2019 Jul 16. PMID: 31230397.
38. Li Y, Delcher PC, **Brown JD**, Wei YJ, Reisfield GM, Winterstein AG. Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: an interrupted time series analysis. *Drug and Alcohol Dependence*. 2019 Sep 1;202:172-177. doi: 10.1016/j.drugalcdep.2019.05.025. Epub 2019 Jul 19. PMID: 31352307.
39. Riaz M, **Brown JD**. Association of Adverse Drug Events with Hospitalization Outcomes and Costs in Older Adults in the United States: Analysis using Nationwide Readmissions Database. *Pharmaceutical Medicine.* 2019 Aug;33(4):321-329. doi: 10.1007/s40290-019-00286-z. PMID: 31933184.
40. **Brown JD**, Smith SM, Strotmeyer ES, Kritchevsky SB, Gill TM, Blair SN, Fielding RA, Buford TW, Pahor M, Manini TM. Comparative effects of ACE inhibitors and ARBs on response to a physical activity intervention in older adults: results from Lifestyle Interventions for Elders (LIFE) study. *Journal of Gerontology: Medical Sciences*. 2020 Apr 17;75(5):1010-1016. doi: 10.1093/gerona/glz120. PMID: 31070702; PMCID: PMC7164526.
41. **Brown JD**, Henriksen C, Vozmediano V, Schmidt S. Real-World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended Release Case Study. *Journal of Clinical Pharmacology*. 2019 Sep;59(9):1275-1284. doi: 10.1002/jcph.1436. Epub 2019 May 14. PMID: 31087552.

42. Kim S, Sharma VD, Lingineni K, Farhan N, Fang L, Zhao L, **Brown JD**, Cristofoletti R, Vozmediano V, Ait-Oudhia S, Lesko L, Trame MN, Schmidt S. Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study. *Journal of Clinical Pharmacology.* 2019 Sep;59(9):1266-1274. doi: 10.1002/jcph.1433. Epub 2019 May 14. PMID: 31087554.
43. **Brown JD**. Higher insulin expenditures associated with utilization of free medication samples. *Research in Social and Administrative Pharmacy*. 2019 Apr 21:S1551-7411(19)30369-9. doi: 10.1016/j.sapharm.2019.04.001. Epub ahead of print. PMID: 31027965.
44. Goodin AJ, **Brown JD**, Delcher PC, Freeman P, Talbert JC, Roussos-Ross D. Perception of Prescription Drug Monitoring Programs as a Prevention Tool in Primary Medical Care. *Research in Social and Administrative Pharmacy.* 2019 Mar 26:S1551-7411(19)30190-1. doi: 10.1016/j.sapharm.2019.03.012. Epub ahead of print. PMID: 30935769; PMCID: PMC6763359.
45. Dawwas G, **Brown JD**, Dietrich EA, Park H. Can apixaban prevent venous thromboembolism better than rivaroxaban? – Authors' reply. *The Lancet Haemotology*. 2019 Apr;6(4):e181-e182. doi: 10.1016/S2352-3026(19)30049-3. PMID: 30926080.
46. Pham PN, **Brown JD**. Real-world adherence for direct oral anticoagulants in newly diagnosed atrial fibrillation cohort: Does the dosing interval matter? *BMC Cardiovascular Disorders*. 2019 Mar 19;19(1):64. doi: 10.1186/s12872-019-1033-3. PMID: 30890131; PMCID: PMC6423818.
47. Thai T, Wang CY, Chang CY, **Brown JD**. Central Nervous System Effects of Oral Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*. 2019 Feb 22;8(2):268. doi: 10.3390/jcm8020268. PMID: 30813242; PMCID: PMC6406625.
48. Rhew K, Reams V, **Brown JD**, Winterstein AG. Commentary on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. *Annals of Medicine*. 2019 Feb;51(1):97-98. doi: 0.1080/07853890.2019.1581941. Epub 2019 Apr 1. PMID: 30801227.
49. Dawwas G, **Brown JD**, Dietrich EA, Park H. Comparative Effectiveness and Safety of Apixaban and Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism and Adverse Bleeding Events in Patients with Venous Thromboembolism. *The Lancet Haemotology*. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14. PMID: 30558988.
50. Olasupa OO, Xiao H, **Brown JD**. Relative Clinical and Cost Burden of Community-Acquired Pneumonia Hospitalizations in Older Adults in the United States—A Cross-Sectional Analysis. *Vaccines*. 2018 Aug 31;6(3):59. doi: 10.3390/vaccines6030059. PMID: 30200286; PMCID: PMC6161150.
51. Pham PN, Sarayani A, Chen, M, Xiao H, **Brown JD**. Risk factors associated with 7-day versus 30-day readmissions among patients with heart failure using the Nationwide Readmission Database. *Medical Care*. 2019 Jan;57(1):1-7. doi: 10.1097/MLR.0000000000001006. PMID: 30363021.
52. **Brown JD**, Harnett J, Chambers R, Sato R. The relative burden of community-acquired pneumonia hospitalizations in older adults: an observational cohort study in the United States. *BMC Geriatrics.* 2018 Apr 16;18(1):92. doi: 10.1186/s12877-018-0787-2. PubMed PMID: 29661135; PubMed Central PMCID: PMC5902892.
53. Goodin AJ, Chen M, Raissi D, Han Q, Xiao H, **Brown JD**. Patient and Hospital Characteristics Predictive of Inferior Vena Cava Filter Usage in Venous Thromboembolism Patients: A Study from the 2013-2014 Nationwide Readmissions Database. *Medicine*. 2018 Mar;97(12):e0149.

doi: 10.1097/MD.0000000000010149. PubMed PMID: 29561421; PubMed Central PMCID: PMC5895325.

54. Chen M, Goodin AJ, Raissi D, Han Q, Xiao H, **Brown JD**. Hospital-level Variation in Vena Cava Filter Utilization for Patients with Venous Thromboembolism: Implications for quality of care. *Vascular Medicine*. 2018 Aug;23(4):365-371. doi: 10.1177/1358863X18768685. PMID: 29781388.
55. **Brown JD**, Talbert JC, Pennington R, Han Q, Raissi D. Non-retrieval of inferior vena cava filters as a patient safety concern: evaluation of a new process improvement project to increase retrieval rates in a vascular and interventional radiology clinic. *Patient Safety in Surgery*. 2018 Mar 20;12:5. doi: 10.1186/s13037-018-0151-7. eCollection 2018. PubMed PMID: 29560028; PMCID: PMC5859390.
56. **Brown JD**, Goodin AJ, Lip GYP, Adams VR. Risk stratification for bleeding complications in patients with venous thromboembolism: Application of the HAS-BLED bleeding score during the first six months of anticoagulant treatment. *Journal of the American Heart Association.* 2018 Mar 7;7(6). pii: e007901. doi: 10.1161/JAHA.117.007901. PubMed PMID: 29514808; PMCID: PMC5907554.
57. **Brown JD**, Raissi D, Han Q, Adams V, Talbert JC. Commentary: Vena Cava Filter Retrieval Rates and Factors Associated with Retrieval in a Large U.S. Cohort. *Journal of Vascular Surgery-Venous and Lymphatic Disorders*. 2018. Jan;6(1):135-136. doi:10.1016/j.jvsv.2017.10.009
58. El-Refai SM, Black EP, Adams VR, Talbert JC, **Brown JD**. Statin use and venous thromboembolism in cancer: a large, active comparator, propensity score matched cohort study. *Thrombosis Research*. 2017 Oct;158:49-58. doi: 10.1016/j.thromres.2017.08.001. Epub 2017 Aug 10. PMID: 28822240; PMCID: PMC5755594.
59. **Brown JD**, Sheer R, Pasquale M, Sudharshan L, Axelsen K, Subedi P, Wiederkehr D, Brownfield F, Kamal-Bahl S. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States. *Value in Health*. 2018 Jan;21(1):33-40. doi: 10.1016/j.jval.2017.07.009. Epub 2017 Aug 30. PMID: 29304938. ***Editors' Choice***
60. **Brown JD**, Raissi D, Han Q, Adams VR, Talbert JC. Vena cava filter retrieval rates and factors associated with retrieval in a large United States cohort. *Journal of the American Heart Association.* 2017 Sep 4;6(9):e006708. doi: 10.1161/JAHA.117.006708. PMID: 28871041; PMCID: PMC5634307.
61. Triplett K, Goodin AJ, Delcher PC, **Brown JD**, Roussos-Ross K. Opioid drug exposures and health care utilization measures associated with Neonatal Abstinence Syndrome in Florida 2011-2015. *Journal of Gynecology & Obstetrics*. 2017;1:018.
62. **Brown JD**, Goodin AJ, Talbert JC. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. *Journal of Rural Health*. 2018 Dec;34(1):6-13. doi: 10.1111/jrh.12251. Epub 2017 Jul 7. PMID: 28685864; PMCID: PMC5752583.
63. El-Refai SM, **Brown JD**, Black EP, Talbert JC. Immune checkpoint inhibition and the prevalence of autoimmune disorders among lung and renal cancer patients. *Cancer Informatics*. 2017 Jun 1;16:1176935117712520. doi: 10.1177/1176935117712520. PMID: 28615920; PMCID: PMC5459511.
64. El-Refai SM, **Brown JD**, Arnold SM, Black EP, Leggas M, Talbert JC. Epidemiological analysis along the mevalonate pathway reveals improved cancer survival in patients receiving statins

alone and in combination with bisphosphonates. *JCO Clinical Cancer Informatics*. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00010. PMID: 30657380; PMCID: PMC6467073.

65. **Brown JD**, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment naïve atrial fibrillation patients: an update using 2013-2014 data. *J Manag Care Spec Pharm.* 2017 Sep;23(9):958-967. doi: 10.18553/jmcp.2017.23.9.958. PMID: 28854077; PMCID: PMC5747360.
66. Pauly NJ, Talbert JC, **Brown JD**. Empirical assessment of the impact of low-cost generic programs on adherence-based quality measures. *Pharmacy*. 2017 Mar 8;5(1). pii: E15. doi: 10.3390/pharmacy5010015. PubMed PMID: 28970427; PubMed Central PMCID: PMC5419384.
67. **Brown JD**, Adams VR, Moga DC. Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma. *Healthcare*. 2016 Dec 20;4(4):93. doi: 10.3390/healthcare4040093. PMID: 27999418; PMCID: PMC5198135.
68. **Brown JD**, Pauly NJ, Doshi PA, Talbert JC. Neonatal Abstinence Syndrome rates amid efforts to combat the opioid abuse epidemic. *JAMA Pediatr*. 2016 Nov 1;170(11):1110-1112. doi: 10.1001/jamapediatrics.2016.2150. PMID: 27669331; PMCID: PMC5444666.
69. **Brown JD**, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve non-valvular atrial fibrillation. *J Manag Care Spec Pharm.* 2016 Nov;22(11):1319-1329. doi: 10.18553/jmcp.2016.22.11.1319. PMID: 27783556; PMCID: PMC5751430.
70. **Brown JD** and Talbert JC. Hospital variation and patient characteristics associated with vena cava filter utilization. *Medical Care*. 2017 Jan;55(1):31-36. doi: 10.1097/MLR.0000000000000599. PMID: 27547945; PMCID: PMC5145746.
71. **Brown JD**, Sheer RL, Null KD, Pasquale MK, Sato R. The relative burden of community-acquired pneumonia in seniors. *Am J Prev Med*. 2016. doi:10.1016/j.amepre.2016.05.015
72. **Brown JD**, Shewale AR, Dherange P, Talbert JC. A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC eras. *Drugs Aging.* 2016 Jun;33(6):427-36. doi: 10.1007/s40266-016-0369-y. PMID: 27154397.
73. **Brown JD**, Talbert JC. Variation in the Use of Vena Cava Filters for Venous Thromboembolism in Kentucky. *JAMA Surg*. 2016 Oct 1;151(10):984-986. doi: 10.1001/jamasurg.2016.1004. PMID: 27464070; PMCID: PMC5444656.
74. **Brown JD**, Pauly NJ, Talbert JC. The Prevalence and Predictors of Low-Cost Generic Program Use in a Nationally Representative Uninsured Population. *Pharmacy*. 2016 Mar 4;4(1):14. doi: 10.3390/pharmacy4010014. PMID: 28970387; PMCID: PMC5419353.
75. **Brown JD**, Adams VR. Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. *Healthcare*. 2016 Feb 26;4(1):16. doi: 10.3390/healthcare4010016. PMID: 27417604; PMCID: PMC4934550.
76. **Brown JD**, Doshi PA, Talbert JC. Utilization of free medication samples in the United States in a nationally representative sample: 2009-2013. *Res Social Adm Pharm*. 2017 Jan-Feb;13(1):193-200. doi: 10.1016/j.sapharm.2016.01.006. Epub 2016 Jan 30. PMID: 26895807; PMCID: PMC5737018.
77. **Brown JD**, Hutchison LC, Li C, Painter JT, Martin BC. Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United

States. *J Am Geriatr Soc*. 2016;64(1):22-30. doi:10.1111/jgs.13884. PMID: 26782849 PMCID: PMC5287350.

78. Pauly NJ, Talbert JC, **Brown JD**. Low-Cost Generic Program Use By Medicare Beneficiaries: Implications For Medication Exposure Misclassification In Administrative Claims Data. *J Manag care Spec Pharm*. 2016 Jun;22(6):741-51. doi: 10.18553/jmcp.2016.22.6.741. PMID: 27231801; PMCID: PMC5737016.
79. Pauly NJ, **Brown JD**. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults. *J Manag care Spec Pharm*. 2015 Dec;21(12):1162-70. doi: 10.18553/jmcp.2015.21.12.1162. PMID: 26679965.
80. **Brown JD**, Ratermann KR, Talbert JC, Adams VR. Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort. *JHEOR*. 2015;3(2):214-223.
81. Pauly NJ, Talbert JC, **Brown JD**. The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population. *Drugs - Real World Outcomes*. 2015;2(4):411-419. doi: 10.1007/s40801-015-0051-4. Epub 2015 Dec 1. PMID: 26690285; PMCID: PMC4674520.
82. Shewale AR, Borse MS, **Brown JD**, Li C. Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers. *Drug Alcohol Depend*. 2015 Sep 1;154:132-8. doi: 10.1016/j.drugalcdep.2015.06.028. Epub 2015 Jun 27. PMID: 26169448.
83. **Brown JD**, Li C. Characteristics of online pharmacy users in a nationally representative sample. *J Am Pharm Assoc*. 2014 May-Jun;54(3):289-94. doi: 10.1331/JAPhA.2014.13169. PMID: 24816356.
84. Gupta PK, **Brown JD**, Biju PG, et al. Development of high-throughput HILIC-MS/MS methodology for plasma citrulline determination in multiple species. *Anal. Methods*. 2011;3(8):1759-1768. doi:10.1039/c1ay05213f.

Reviews

85. **Brown JD,** Rivera Rivera KJ, Cresp LY, Doenges MR, Auchey I, Pham T, Goodin AJ. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. *Journal of Clinical Pharmacology*. 2021 (In press). ***Invited Article for Special Issue.**
86. **Brown JD**. Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions. *Journal of Clinical Medicine*. 2020 Mar 27;9(4):919. doi:10.3390/jcm9040919. PMID: 32230864.PMCID:PMC7231229
87. **Brown JD**, Cicali B, Pham PN, Schmidt S, Lip GYH. Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs. *European Heart Journal – Cardiovascular Pharmacology.* 2020 Jul 1;6(3):155-156. doi: 10.1093/ehjcvp/pvz053. PMID: 31593242.
88. **Brown JD**, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. *Journal of Clinical Medicine*. 2019, 8(7), 989; https://doi.org/10.3390/jcm8070989. PMID:31288397. PMCID:PMC6678684.
89. Goodin AJ, Raissi D, Han Q, **Brown JD**. A Review of Institutional Interventions to Increase Vena Cava Filter Retrieval Rates. *Annals of Vascular Surgery*. 2018 Aug;51:284-297. doi: 10.1016/j.avsg.2018.02.010. Epub 2018 Apr 13. PMID: 29655810.
90. Goodin AJ, Delcher PC, Valenzuela C, Wang X, Zhu Y, Roussos-Ross D, **Brown JD**. The power and Pitfalls of Big Data Research in Obstetrics & Gynecology: A Consumer's Guide.

Obstetrics & Gynecology Survey. 2017 Nov;72(11):669-682. doi: 10.1097/OGX.0000000000000504. PubMed PMID: 29164265; PMCID: PMC5704657.

Commentary and Letters

91. Sajdeya R, **Brown JD**, Goodin AJ. Perinatal Cannabis Exposures and Autism Spectrum Disorders. *Medical Cannabis and Cannabinoids*. 2021 (In press).
92. **Brown JD**, Goodin AJ. Evidence in Context: High risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. *Medical Cannabis and Cannabinoids*. 2021. https://doi.org/10.1159/000514732.
93. Goodin AJ, Winterstein AG, Cook R, Wang Y, **Brown JD**. Introducing Commentary Series: "Evidence in Context". *Medical Cannabis and Cannabinoids*. 2020 (In press). https://doi.org/10.1159/000512684.
94. **Brown JD.** What do you meme, professor? An experiment using "memes" in pharmacy education. *Pharmacy.* 2020 Oct 29;8(4):202. doi: 10.3390/pharmacy8040202. PMID:33138086. PMCID:PMC7712418.
95. **Brown JD**. [Commentary] Counting COVID-19 sequelae as direct deaths. *Annals of Internal Medicine*. 2020.
96. **Brown JD**. A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative. J Manag Care Spec Pharm. 2020 Aug;26(8):1050. doi: 10.18553/jmcp.2020.26.8.1050. PMID: 32715968.
97. **Brown JD**. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic. *Research in Social and Administrative Pharmacy*. 2020 Mar 31:S1551-7411(20)30300-4. doi: 10.1016/j.sapharm.2020.03.020. Epub ahead of print. PMID: 32273254.
98. **Brown JD**. Antihypertensives and COVID-19. *The Lancet Respiratory Medicine*. 2020 May 1;8(5):E28. doi:https://doi.org/10.1016/S2213-2600(20)30158-2.
99. Happe L, **Brown JD**, Gatwood J, Wang SV, Schneeweiss S. Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research. *Journal of Managed Care and Specialty Pharmacy*. 2020 Mar;26(3):268-274. doi: 10.18553/jmcp.2020.26.3.268. PMID: 32105168.
100. **Brown JD**. Proton Pump Inhibitors and Gynecomastia: Selection of active comparisons in pharmacoepidemiology. *Pharmacotherapy*. 2019 Jul;39(7):791. doi: 10.1002/phar.2275. Epub 2019 Jun 21. PMID: 31063650.
101. Schmidt S, Kim S, Vozmediano V, Cristofoletti R, Winterstein A, **Brown JD**. Pharmacometrics, PBPK, QSP – What's Next? - Joining mechanistic and epidemiological approaches. *CPT: Pharmacometrics & Systems Pharmacology*. 2019 Jun;8(6):352-355. doi: 10.1002/psp4.12425. Epub 2019 Jun 9. PMID: 31179639; PMCID: PMC6618101.
102. **Brown JD**, Goodin AJ. The prevalence of drivers under the influence of medical cannabis must be considered within proper context. *Research in Social and Administrative Pharmacy.* 2019 Nov;15(11):1372-1373. doi: 10.1016/j.sapharm.2019.01.015. Epub 2019 Jan 28. PMID: 30709730
103. Lesko LJ, Vozmediano V, **Brown JD**, Winterstein AG, Zhao P, Lipport J, Hochel J, Chaturvedula A, White A, Schmidt S. Establishing a multidisciplinary framework to study drug-drug interactions of hormonal contraceptives by integration of pharmacometrics, pharmacoepidemiology, and pharmacoeconomics. *CPT Pharmacometrics and Systems*

Pharmacology. 2018 Nov;7(11):706-708. doi: 10.1002/psp4.12357. Epub 2018 Oct 23. PMID: 30260082; PMCID: PMC6263668.

104. **Brown JD**, Goodin AJ, Lip GYH. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: comment. *Journal of Thrombosis and Haemostasis*. 2018 Dec;16(12):2537-2539. doi: 10.1111/jth.14301. Epub 2018 Oct 15. PMID: 30240546.
105. **Brown JD** and Pham PN. The need for deliberate and thorough design and critique of observational comparative effectiveness research: the case of direct acting oral anticoagulants. *Research in Social and Administrative Pharmacy*. 2018 Nov;14(11):1085-1087. doi: 10.1016/j.sapharm.2018.07.012. PMID: 30041916.
106. **Brown JD** and Goodin AJ. Mass Casualty Shooting Venues, Types of Firearms, and Age of Perpetrators in the United States, 1982-2018. *American Journal of Public Health.* 2018 Oct;108(10):1385-1387. doi: 10.2105/AJPH.2018.304584. Epub 2018 Aug 23. PMID: 30138068; PMCID: PMC6137781.
107. **Brown JD** and Nolte JN. Expanded buprenorphine prescribing privileges: Sandbagging in the midst of the flood? *Research in Social and Administrative Pharmacy*. 2018 Jun;14(6):617-618. doi: 10.1016/j.sapharm.2018.03.001. Epub 2018 Mar 3. PMID: 29525482.
108. **Brown JD**. Is midazolam a constitutional or pharmacological alternative in lethal injections? *Research in Social and Administrative Pharmacy*. 2018 Jan;14(1):118-119. doi: 10.1016/j.sapharm.2017.08.007. Epub 2017 Sep 5. PMID: 28888343.
109. **Brown JD**, Talbert JC. Treatment of opioid use disorder during pregnancy may increase cases of neonatal abstinence syndrome – Reply. *JAMA Pediatrics*. 2017 Jul 1;171(7):707-708. doi: 10.1001/jamapediatrics.2017.0863. PMID: 28459984.
110. **Brown JD**, Shewale AR, Dherange P, Talbert JC. Treatment with anticoagulants for stroke prevention in atrial fibrillation is increasing but further improvements are needed. *J Am Coll Cardiol*. 2016 Dec 6;68(22):2492. doi: 10.1016/j.jacc.2016.06.082. PMID: 27908358.
111. **Brown JD**, Hutchison LC, Martin BC. Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. *J Gerontol Geriatr Res*. 2016;5:321. doi: 10.4172/2167-7182.1000321.
112. **Brown JD**. Low-cost generic drug programs in the United States: implications for payers and researchers. *GaBI Journal*. 2016;5(1):6-7 doi: 10.5639/gabij.2016.0501.003

Other Publications

113. "Career Paths in Industry and Population Health: An ASHP eReport." Jaclyn Boyle, Sara J. Beis, Joshua D. Brown, and Ivy Muteithia. 2017.
114. "Demystifying the financial barriers of pursuing a graduate degree." Joshua Brown. *Student Pharmacist,* November 16, 2015.

Invited Talks

1. **Brown JD**. *Workshop/Syposium*. "Real-World Evidence of drug interactions with hormonal contraceptives." Application of Exposure-Bracketing to Streamline the Development of Contraceptive Products. Bill and Melinda Gates Foundation. December 2-3, 2020.
2. **Brown JD**. *Symposium.* Cannabis, THC, and CBD: A Paradigm Shift to be Regarded as Medical Products in Research and Education. American College Health Association Annual Meeting. Chicago, IL, May 24-28, 2020.

3. **Brown JD.** *Symposium (speaker and organizer).* Translational collaborations between pharmacology and pharmacoepidemiology to enhance real-world evidence. International Society for Pharmacoepidemiology Mid-Year Meeting. Orlando, FL, April 18-21, 2020.
4. **Brown JD**. *Webinar/Continuing Education.* Drug-drug and drug-disease interaction potential of cannabis. Innovatix/Premier Lunch N Learn Webinar. July, 2020.
5. **Brown JD.** *Symposium.* A multi-disciplinary collaboration using pharmacometrics, pharmacoepidemiology, and pharmacoeconomics for drug efficacy and safety questions. FIP PSWC. Montreal, Canada. May 22-27, 2020.
6. **Brown JD**. *Webinar/Continuing Education.* Real-World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended-Release Case Study. March 18, 2020.
7. **Brown JD**. Integrating Pharmacometrics and Pharmacoeconomics to Predict the Clinical and Cost Effectiveness of Future Generic Anticoagulants. Global Gator Symposium, June 29, 2019. Reims, FR.
8. **Brown JD**. A multi-disciplinary collaboration using pharmacometrics, pharmacoepidemiology, and pharmacoeconomics for efficacy and safety questions related to generic substitution. Lake Nona Leadership Meeting and Symposium, March 11-12, 2019. Lake Nona, FL.
9. **Brown JD**. Community-acquired pneumonia: Relative burden and missed opportunities in an era of chronic diseases. Clinical Translational Aging Research Seminar. University of Florida Institute on Aging and Malcolm Randall VA GRECC. February 5, 2019.
10. **Brown JD**. Data linkage and secondary analysis of the LIFE trial. Clinical Translational Aging Research Seminar. University of Florida Institute on Aging and Malcolm Randall VA GRECC. February 5, 2018.
11. **Brown JD**. How can we create synergies between pharmacometrics, pharmacoepidemiology, and pharmacoeconomics? Lake Nona Leadership Meeting and Symposium, March 19-20, 2018. Lake Nona, FL.

Selected Poster and Podium Abstracts

1. Pham P, Albogami Y, Cicali B, Squires P, Sarayani A, Thai T, Reams V, Rhew K, Goodin A, Schmidt S, Winterstein AG, **Brown JD**. Risk of thromboembolic events associated with concomitant use of oral hormonal contraceptives and selective serotonin reuptake inhibitors. Presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidem Drug Saf* 2020;29(Suppl 3):613 https://doi.org/10.1002/pds.5114.
2. Costales B, **Brown JD**, Henriksen C, Goodin AJ. Off-label Gabapentin Utilization for Psychiatric Indications Using the Food and Drug Administration Adverse Event Reporting System Database from 1993-2019. Presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidemiology & Drug Safety*, 2020;29(S3):4936.
3. Vouri SM, Chen J, Sparkman J, **Brown JD**, Shao H, Salles A, Micek ST. Lack of insulin secretagogue deprescribing and risk of severe hypogylcemia following bariatric surgery. Presented at the 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. *Pharmacoepidemiol Drug Safety*. 2020;29(S3):592.

4. **Brown JD**, Cicali B, Henriksen C, Malaty I, Okun M, Armstrong M. Comparative pharmacovigilance analyses of pimavanserin and mortality in Parkinson's disease. Pharmacoepidemiol Drug Safety. 2020;29(S3):2507. https://doi.org/10.1002/pds.5114
5. Shah CH and **Brown JD** (2020). PNS59 Reliability and Validity of the SF-12V2 Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the US Older Adult Population. *Value in Health Regional Issues*, *22*, S91-S92. doi:https://doi.org/10.1016/j.vhri.2020.07.478
6. Costales B, **Brown JD**, Goodin AJ. Outpatient Off-label Gabapentin Utilization from 2011 to 2015 Among United States Adults. International Society of Pharmacoeconomics and Outcomes Research Conference (Virtual ISPOR 2020), May 18-20, 2020. Value in Health. May 2020;23(S1):S137. doi.org/10.1016/j.jval.2020.04.334.
7. Sarayani A, **Brown JD**, Goodin AJ, Cicali B, Henriksen C, Schmidt S, Winterstein AG. Effect of enzyme-inducing antiepileptic drugs on failure of oral low-dose hormonal contraceptives. *International Society of Pharmacoepidemiology Mid-Year Meeting.* Orlando, FL, April 18-21, 2020.
8. Pham P, Henriksen C, Albogami Y, Squires P, Goodin A, Reams V, Rhew K, Schmidt S, Winterstein AG, **Brown JD**. Risk of thromboembolic events associated with drug-drug interactions between oral hormonal contraceptives and selective serotonin reuptake inhibitors. *International Society of Pharmacoepidemiology Annual Conference*. Philadelphia, PA, August 24-28, 2019.
9. Rhew K, Reams V, **Brown JD**, Winterstein AG. Association between the risk of venous thrombosis and antidepressants: a meta-analysis. *International Society of Pharmacoepidemiology Annual Conference*. Philadelphia, PA, August 24-28, 2019.
10. Goodin AJ, Squires P, Henriksen C, Jugl S, Winterstein AG, **Brown JD**. Prevalence of Prescription Contraceptives Following the Affordable Care Act Contraception Coverage Mandate in a Commercially Insured Population. *Academy Health Annual Research Meeting*. Washington, D.C., June 1-4, 2019.
11. Squires P, Goodin AJ, Henriksen C, Jugl S, Winterstein AG, **Brown JD**. Prevalence of Potential Drug-Drug Interactions involving Hormonal Contraceptive Agents Among Women of Childbearing Age in a Commercially Insured Population. *ISPOR Annual Meeting.* New Orleans, LA, May 18-22, 2019.
12. **Brown JD**, Schmidt S. Combining Real-World Data Analysis and Pharmacometrics to Assess the Value of Generic Drugs: Retrospective and Prospective Examples in Cardiology Therapeutic Areas. Academy of Managed Care Pharmacy Nexus 2019. National Harbor, MD, October 29-November 1, 2019. *Journal of Managed Care & Specialty Pharmacy.* 25(10-a Suppl), pp. S1–S100. https://doi.org/10.18553/jmcp.2019.25.10-a.s1.
13. Goodin AJ, Huang JL, Park H, Hincapie Castillo JM, **Brown JD**, Costales B, Lo-Ciganic W. Trends in Controlled Substance Utilization in Arizona from 2011-2016, by Prescription Class. 2019 Addiction Health Services Research (AHSR), Salt Lake City, Utah, USA, October 16-18, 2019.
14. Goodin AJ, Huang JL, Park H, Hincapie Castillo JM, **Brown JD**, Costales B, Lo-Ciganic W. Change in Buprenorphine Prescriptions for Opioid Use Disorder Indications in Arizona from 2011-2016. 2019 Addiction Health Services Research (AHSR), Salt Lake City, Utah, USA, October 16-18, 2019.
15. Cicali B, Schmidt S, **Brown JD**. (2019) Novel Application of Pharmacoepidemiology for Examination of Possible Pharmacokinetic/Pharmacodynamic Mechanisms of Macrolide Antibiotic Resistance. American College of Clinical Pharmacology Annual Meeting, September 15-17, 2019. Chicago, IL. Clinical Pharmacology in Drug Development 8(S1):78.

16. Wang CY, Kim S, Lingineni K, Schmidt S, Diaby V, **Brown JD**. Predicting the Cost-effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation. International Society for Pharmacoeconomics and Outcomes Research, New Orleans Ernest N. Morial Convention Center, New Orleans, LA, USA, May 18-22, 2019. Value in Health, Volume 22, Issue S1 (2019 May).
17. Pham PN, **Brown JD**. Trend in 3-day, 7-day and 30-day heart failure readmission rates from 2010 to 2015 in the Nationwide readmissions database. *Pharmacoepidemiol Drug Saf.* 2019; 28(S2): 85-86.https://doi.org/10.1002/pds.4864.
18. Wang X, **Brown JD**, Xiao H, Zimmermann EM, Winterstein AG. Validity of low birth weight and small for gestational age in the Medicaid analytic extract database. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019. Pharmacoepidemiology & Drug Safety. Aug 2019, 28 (S2), 156. DOI: 10.1002/pds.4864.
19. Goodin A, **Brown JD**, Freeman P, Henry S, Talbert J, Delcher C. Obstetrician/Gynecologist Perception of Prescription Drug Monitoring Program Effectiveness [15I]. *Obstetrics & Gynecology*. 133:99S, May 2019. American College of Obstetricians and Gynecologists' 2019 Annual Clinical and Scientific Meeting, May 3–6, 2019, Nashville, TN.
20. Roussos-Ross D, Delcher C, Goodin A, **Brown JD**, Bae J. Perceptions and Utilization of Prescription Drug Monitoring Programs: A Survey of ACOG members [1Q]. *Obstetrics & Gynecology*. 133:181S, May 2019. American College of Obstetricians and Gynecologists' 2019 Annual Clinical and Scientific Meeting, May 3–6, 2019, Nashville, TN.
21. Goodin AJ, Squires P, Henriksen C, Jugl S, Winterstein A, **Brown JD**. Prevalence of Prescription Contraceptives Following the Affordable Care Act Contraception Coverage Mandate in a Commercially Insured Population. Academy Health 36th Annual Research Meeting. Women's Health Session. June 3, 2019. Washington, DC.
22. Nandakumar N, Jugl S, **Brown JD**, Simpkins A, Wilson CA, Khanna A, Youn TS, Kelly AG. Demographics, Risk Factors and Outcomes of Stroke in Young Adults Aged 18-45 Years in Comparison With Those Older Than 45 Years. INTERNATIONAL STROKE CONFERENCE 2019. February 2019. Stroke 50(Suppl_1). DOI:10.1161/str.50.suppl_1.WP245.
23. Simpkins A, Sarayani A, Nandakumar N, **Brown JD**, Wilson CA, Khanna A, Youn TS, Kelly AG. Vascular Dementia Amongst Patients Included in the National Inpatient Sample Database 2006-2014 is not on the Decline. INTERNATIONAL STROKE CONFERENCE 2019. February 2019. Stroke 50(Suppl_1). DOI:10.1161/str.50.suppl_1.TMP113
24. **Brown JD**, Kritchevsky S, Buford T, Gill T, Strotmeyer E, Smith S, Pahor M, Manini T. ACE inhibitors and ARBs influence on mobility outcomes in older adults: Results from the LIFE trial. Gerontological Society of America's 70th Annual Scientific Meeting, Boston, Massachusetts, November 14-18, 2018. Innov Aging. 2018 Nov; 2(Suppl 1): 892. Published online 2018 Nov 16. doi: 10.1093/geroni/igy031.3324.
25. Pham PN and **Brown JD**. Real-World Adherence to Dabigatran, Rivaroxaban and Apixaban among Patient with Nonvalvular Atrial Fibrillation: 2010-2015. AMCP Nexus 2018. Orlando, FL, October 22-25, 2018.
26. Kim S, Sharma VD, Lingineni K, Farhan N, Fang L, Zhao L, **Brown JD**, Cristofoletti R, Vozmediano V, Ait-Oudhia S, Lesko L, Trame MN, Schmidt S. A Model and Systems Based Approach to Assess Impact of Potential Pharmacokinetic Differences on Pharmacodynamics and Questions Regarding Generic Substitution – A Case Study on Metoprolol Extended-Release Tablets. American Conference on Pharmacometrics. San Diego, CA, October 7-10, 2018.

27. Wang W, Re VL, Xiao H, **Brown JD**, Guo Y, Park H. Direct-acting Antivirals Reduce the Risk of Non-hepatic Cancers among Hepatitis C Virus Infected Patients. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic, August 22-26, 2018. *Pharmacoepidemiology & Drug Safety*. Aug 2018, 27 (S2), 387-388. DOI: https://doi.org/10.1002/pds.4629 *Presenting author for Spotlight Poster Session
28. Sarayani A, **Brown JD**, Pham PN, Youn T, Xiao H. Association Between Recombinant Tissue Plasminogen Activator and In-Hospital Mortality/30-Day Readmission Among Mechanical Thrombectomy Patients: A Retrospective Cohort Study. International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Baltimore, USA, May 19-23, 2018. Value in Health (21) S68.
29. Wang W, Re VL, Xiao H, **Brown JD**, Guo Y, Park H. Incidence of Hepatocellular Carcinoma and Extrahepatic Cancers Among HCV-Infected Patients in the Era of Direct-Acting Antivirals. International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Baltimore, USA, May 19-23, 2018. *Value in Health*, May 2018, *21*, pp.S12-S13. DOI: https://doi.org/10.1016/j.jval.2018.04.063
30. **Brown JD**. Strengths and Challenges of Pharmacoeconomics in Valuing Real-World Outcomes. Lake Nona Leadership Meeting and Symposium, March 19-20, 2018. Lake Nona, FL.
31. Pham PN, **Brown JD**. Adverse bleeding events associated with co-prescribing of oral anticoagulants and calcium channel blockers. Lake Nona Leadership Meeting and Symposium, March 19-20, 2018. Lake Nona, FL.
32. Raissi D, Han Q, Goodin A, **Brown JD**. Inferior vena cava filter retrieval initiatives: A 2008-2017 systematic review. *Journal of Vascular and Interventional Radiology.* International Symposium on Endovascular Therapy (ISET). Hollywood, FL, February 3-7, 2018.
33. Raissi D, Han Q, Goodin A, **Brown JD**. Tired of low IVC filter retrieval rates: Here is the least you can do!!! *Journal of Vascular and Interventional Radiology.* International Symposium on Endovascular Therapy (ISET). Hollywood, FL, February 3-7, 2018.
34. **Brown JD**, Goodin AJ, Talbert JC. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Incidence and Access to Opioid Abuse Treatment. International Society for Pharmacoepidemiology 2017 Annual Meeting. Montreal, Canada, August 26-30, 2017. ***Best poster award**
35. Chen M, **Brown JD**. Causes of Readmission after Venous Thromboembolism with or without Vena Cava Filters in the United States: Nationwide Readmission Database 2013-2014International Society for Pharmacoepidemiology 2017 Annual Meeting. Montreal, Canada, August 26-30, 2017. ***Poster Finalist**
36. Kim S, Lingineni K, Meng A, Sharma VD, Miller R, Trame MN, Fang L, **Brown JD**, Lesko LJ, Schmidt S. A Model and Systems Based Approach to Safety and Efficacy Questions Related to Generic Substitution - A Direct Oral Anticoagulants Case Study. American Association of Pharmaceutical Scientists 2017 Annual Meeting. San Diego, CA, November 12-15, 2017.
37. **Brown JD**, El-Refai SM, Black EP, Adams VR, Talbert JC. Statin Use and Venous Thromboembolism in Cancer: A Large, Propensity Score Matched Cohort Study in the United States. XXVI Congress of the International Society on Thrombosis and Haemostasis and 63rd Annual Scientific and Standardization Committee, Berlin, Germany, July 8-13, 2017.
38. **Brown JD**, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment Naïve Atrial Fibrillation Patients: 2013-2014. XXVI Congress of the International Society on Thrombosis and Haemostasis and 63rd Annual Scientific and Standardization Committee, Berlin, Germany, July 8-13, 2017.

39. **Brown JD**, Talbert JC. Vena Cava Filter Retrieval Rates and Factors Associated with Retrieval in the United States. XXVI Congress of the International Society on Thrombosis and Haemostasis and 63rd Annual Scientific and Standardization Committee, Berlin, Germany, July 8-13, 2017.
40. **Brown JD**, Talbert JC. Variation in the use of vena cava filters in Kentucky hospitals. International Conference for Pharmacoepidemiology, Dublin, IRL, August 23-27, 2016.
41. **Brown JD**, Adams VR, Moga DM. Transient impact of treatment exposures and one-year incidence of thrombosis in multiple myeloma: a case-time-control analysis. ISTH SSC Meeting, Montpellier, FR, May 22-25, 2016. ***Podium and poster **Young Investigator Award ***Top Abstract Award ****Presidential Award**
42. **Brown JD**, Pauly N, Talbert J. The Prevalence and Predictors of Low-Cost Generic Program Use in the Pediatric Population. AMCP Annual Meeting, San Francisco, CA, April 19-22, 2016. *Gold Medal Abstract Award
43. **Brown JD**, Sheer R, Null K, Pasquale M, Sato R. The relative burden of community-acquired pneumonia hospitalizations compared to other serious conditions in the older population. AMCP Annual Meeting, San Franciso, CA, April 19-22, 2016. *Silver Medal Abstract Award
44. **Brown JD**, Adams VR, Moga DM. Transient impact of treatment exposures and one-year incidence of thrombosis in multiple myeloma: a case-time-control analysis. ICPE Mid-Year Conference, Baltimore, MD, Apriil 10-12, 2016. *Podium **Abstract scholarship award
45. **Brown JD**, MacLean E, Cisar L, Mardekian J, Harnett J. Treatment patterns and costs associated with axitinib and everolimus treatment for renal cell carcinoma: a commercial health claims analysis. American Society of Clinical Oncology (2015).
46. Pauly NJ, **Brown JD**. Low-Cost Generic Program Use By Medicare Beneficiaries: Implications For Medication Exposure Misclassification In Administrative Claims Data. International Conference for Pharmacoepidemiology (ICPE), Boston, MA, August 22-26, 2015
47. Pauly NJ, **Brown JD**. Use of low-cost generic programs in a nationally representative Medicare population and implications for quality initiatives. ISPOR International Meeting, Philadelphia, PA, May 16-20, 2015. AMCP Annual Meeting, San Francisco, CA. *Gold Medal Abstract Award
48. Pauly NJ, **Brown JD**. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Medicare Beneficiaries. ISPOR International Meeting, Philadelphia, PA, May 16-20, 2015. *Value in Health*. May 2015, 18(3):A265-A266.
49. Pauly NJ, **Brown JD**. Prevalence and determinants of Low-Cost Generic Drug program use in the privately-insured Adult Population. ISPOR International Meeting, Philadelphia, PA, May 16-20, 2015. *Value in Health*. May 2015, 18(3):A265-A266.
50. **Brown JD**, Ratermann K, Talbert J, Adams V. Risk of recurrent VTE or bleed in cancer patients: a time-to-event analysis. Hematology/Oncology Pharmacy Association Annual Conference, 2015, Austin, TX, March 25-28.
51. **Brown JD**, Ratermann K, Talbert J, Adams V. Factors directing anticoagulation treatment in cancer patients with VTE. UHC Pharmacy Council Meeting, Anaheim, CA, December 5-6, 2014.
52. **Brown JD**, Painter J, Li C, Hutchison LC, Martin BC. Adverse Drug Events In The Elderly Occurring In Emergency, Inpatient, And Outpatient Departments In An Administrative Claims Database. International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014. *Value in Health.* May 2014, 17(3):A155. DOI: https://doi.org/10.1016/j.jval.2014.03.904
53. **Brown JD**, Li C. Factors Associated With Online Pharmacy Use In A Nationally Representative Sample. International Society for Pharmacoeconomics and Outcomes Research Annual

International Meeting. New Orleans, LA, USA, May 18-22, 2013. *Value in Health*. May 2013, 16(3):A249.

Grants and research support

Current funding

Bill & Melinda Gates Foundation Schmidt (PI) 11/1/2018 – 10/31/2022
Application of physiologically-based pharmacokinetic models to inform dosing recommendations for hormonal contraceptives co-administered with other medications
Develop qualitative pharmacological and pharmacoepidemiological evidence to inform treatment decisions for hormonal contraceptives and interacting medications
Role: Sub-PI

State of Florida Legislative Appropriations Winterstein (PI) 7/1/2019 – 6/30/2023
Consortium for Medical Marijuana Clinical Outcomes Research
State-wide initiative to assess, fund, and conduct clinical outcomes research on medical cannabis use in the State of Florida.
Role: Faculty Lead for data repository development and linkages (MEMORY)

Consortium for Medical Marijuana Clinical Outcomes Research Brown (PI) 12/1/2019 – 12/31/2020
Characterizing community and physician-level factors associated with medical marijuana prescriber registration and patient access
This project will create a data resource and tool to understand the environmental factors related to use of cannabis in the state of Florida including community and physician level factors.
Role: PI

Completed funding

Hematology/Oncology Pharmacist Association Adams and Brown (co-PIs) 1/1/2016 – 12/31/2016
Cancer-related venous thromboembolism: treatment choice, patterns, and outcomes.
Evaluate treatment patterns and comparative effectiveness and safety of anticoagulants
Role: Co-PI ($40,000)

PhRMA Foundation Brown (PI) 9/1/2017 – 8/31/2018
Comparative effectiveness of direct-acting oral anticoagulants (DOACs) in non-valvular atrial fibrillation (NVAF): Contrasting methodological approaches using real-world data
Establish the comparative effectiveness and safety of DOACs in diverse patient populations.
Iteratively evaluate the impact of study design and methodological approaches for observational data.
Role: PI ($100,000)

FDA 1U01FD005210-01 Lesko (PI) 9/10/2014 – 8/31/2018
Novel oral anticoagulants and adverse drug events.
Develop real-world evidence for hypothesis confirming and generating observations from pharmacometric modeling studies.
Role: Sub-PI ($260,000; 1.3 MILLION)

NIH-NIA P30AG028740 Pahor (PI) 4/1/2017 – 3/30/2019
Claude D. Pepper OAIC, University of Florida Institute on Aging

LIFE's Legacy: Secondary data linkage to evaluate the long-term effects of the Lifestyle Interventions and Independence for Elders (LIFE) trial
Extend follow-up of the LIFE trial to evaluate long-term and cumulative effects of the intervention by linking to administrative claims data. Develop and validate a claims-based computable phenotype for mobility disorders and frailty in older adults.
Role: PI (Junior Scholar)

UF College of Pharmacy PROSPER Cavallari, Winterstein, Brown (MPI) 12/1/2018 – 12/31/2019
Linkage of UF Health electronic health records to Medicare claims data to examine outcomes and opportunities with pharmacogenetic implementation in clinical practice.
This project linked Medicare claims data to UF Health EHR to provide a resource to internal collaborators to expand research opportunities in pharmacogenomics, personalized medicine, and pharmacoepidemiology.
Role: MPI

NIH National Institute on Drug Abuse Hayes (PI) 3/1/2019 – 2/23/2020
Impact of Opioid Dosing Strategies on Pain Scores and Adverse or Unintended Clinical Outcomes (1R36DA046717-01)
This project aims to assess changes in patient-reported pain associated with maintenance or changes in opioid prescriptions in the Veterans Affairs population to inform clinical practice on pain treatment and management.
Role: Consultant

UF Health Quasi-Endowment Fund Brown (PI) 10/1/2019 – 9/30/2020
Quality of care with inferior vena cava filters
This project aims to determine the scope of practice focused on a medical device, inferior vena cava filters, and aims to promote high-value, evidence-based practices within UF Health and collect preliminary data for future grant applications.
Role: PI

Honors, awards, and activities

- ACCP Ambulatory Care Practice and Research Network 2020 Outstanding Paper of the Year Award (2020)
- Phi Lambda Sigma Pharmacy Leadership Society, Faculty Inductee (2020)
- NIH-NIA Loan Repayment Program Award (2020-2022)
- National Academy of Medicine, Emerging Leaders Symposium (2019)
- Academy Health and AHRQ-HCUP Manuscript of the Year, Runner-Up, Policy Section (2019)
- Academy of Managed Care Pharmacy *New Practitioner Award* (2019)
- NIH-NIA Loan Repayment Program Award (2018-2020)
- Entrepreneurship Faculty Fellow, Entrepreneurship & Innovation Center, Warrington College of Business, University of Florida (2017)
- Best poster presentation, "Medical Device" category, ISPE Annual Meeting 2017
- Claude D. Pepper Junior Scholars Program, University of Florida Institute on Aging (2017)
- Young Investigator Award, International Society for Thrombosis and Haemostasis (2017)
- TEDMED 2017 Research Scholar (http://www.tedmed.com/)

- Top 10 Most Read Manuscript in 2016, Journal of Managed Care & Special Pharmacy (JMCP, 2016)
- Gold medal abstract, Academy of Managed Care Pharmacy Annual Meeting (2016)
- Silver medal abstract, Academy of Managed Care Pharmacy Annual Meeting (2016)
- Best Graduate Student Poster, Rho Chi Research Day, University of Kentucky College of Pharmacy (2016)
- Young Investigator Award, International Society for Thrombosis and Haemostasis (2016)
- Milwaukee Presidential ISTH Scientific and Standardization Committee Award (2016)
- Top Abstract Award, ISTH Scientific and Standardization Committee Meeting (2016)
- Student Travel Award, ISPE Annual Conference (2016)
- Student Abstract Award, ISPE Mid-Year Meeting (2016)
- University of Kentucky Graduate Student Travel Award (2015, 2016)
- Student Travel Award for European Congress, International Society for Pharmacoeconomics and Outcomes Research European Congress (2014)
- Paul Ambrose Scholars Program, NIH Association for Prevention Teaching and Research (2013)
- American Association of Colleges of Pharmacy-Wal-Mart Scholars Program (2013)
- Express Scripts Dual Degree Scholar (2012-14)

Professional membership

- International Society on Thrombosis and Haemostasis (Member)
- International Society for Pharmacoepidemiology (Member)
- American Geriatrics Society (Member)
- Academy of Managed Care Pharmacy (Member)
- Association for Prevention Teaching and Research (Member and Scholar)
- Rho Chi Pharmacy Honor Society (Member and Student Officer)
- International Society for Pharmacoeconomics and Outcomes Research (Member and Student Officer)
- Kappa Psi Pharmaceutical Fraternity (Member, Student Officer, National Officer)

Service activities

National/International

- **Expert Panelist**, National Quality Forum Measure Incubator® NVAF-Related Stroke Prevention Strategy, 2020
- **Co-Chair,** International Working Group – Academic Council, Co-Chair, International Society for Pharmacoepidemiology, 2019-2021
- **Member,** International Working Group, Drug Safety Research Unit Centre for Methods and Evidence in Pharmacovigilance, 2019 (permanent)
- **National Academy of Medicine**, Emerging Leader Forum (2019)
- **Editorial Board Member**, *Journal of Clinical Medicine*, 2018 (permanent)
    - *Pharmacology* section
    - *Guest editor for special issue – "Translational Research in Aging, Geriatrics, and Gerontology"*
- **Editorial Advisory Board**, *Journal of Managed Care and Specialty Pharmacy*, 2018-19
    - Chair – Task Group 4, *JMCP* publishing standards review and update
- **Editorial Advisory Board**, *Research in Social and Administrative Pharmacy*, 2019-22

- **Editorial Board,** *Medical Cannabis and Cannabinoids*, 2020

College/University
- **Internal Advisory Board**, Center for Drug Evaluation and Safety, University of Florida, 2019 (permanent)
- **Assistant Director of Graduate Studies**, Department of Pharmaceutical Outcomes & Policy, UF College of Pharmacy, 2018 (permanent)
- **Academic Advisor Task Force**, UF College of Pharmacy 2018
- **Search Committees:** Department of Pharmaceutical Outcomes & Policy: Chair of search for 3 tenure track lines; Member of search for 4 tenure track lines; Department of Pharmacotherapy and Translational Research: Member of search for Chair of Pharmaceutics and Director of CPSP
- **UF COP Research Showcase Judge:** 2017, 2018
- **UF COP Admission interviews:** 2017, 2018, 2019
- **UF COP Scholarship Committee:** 2018-2019
- **AMCP Student Chapter P&T Committee Judge:** 2018, 2019
- **Lake Nona Leadership Council:** 2018 Session planning committee and speaker

Peer-Review Service Activities
- **Grant reviewer (Ad hoc)**: AHRQ Healthcare Safety and Quality Improvement Research Section (2018)
- **Manuscript reviewer**: *JAMA Pediatrics, Journal of Rural Health* (Exceptional Reviewer 2017, 2018, 2019), *Pharmacoepidemiology and Drug Safety (*Exceptional Reviewer, 2018)*, Journal of Managed Care and Specialty Pharmacy, BMJ, Journal of the American Heart Association, PLOS ONE, Addiction, BMC Geriatrics*, *Addiction, Thrombosis Research* (Top Reviewer, 2017)
- **Abstract reviewer**: ISPE, AMCP, ISPOR
- **Program reviewer:** TEDMED 2017, 2018
- **Member and Organizer**, International Conference for Pharmacoepidemiology and Drug Safety Mid-Year Meeting: Local Host and Scientific Planning Committee

Teaching

Graduate Program
- PHA 6266: Introduction to Pharmaceutical Outcomes & Policy, Graduate Program, 4 lectures
- PHA 6935: Life Cycle of a Drug, Graduate Program, 1 lecture
- PHA 6894: Introduction to Graduate Studies, 1 lecture
- PHA 6805: Data Analysis, Interpretation, and Reporting, Course Coordinator

Pharmacy Program
- PHA 5223: Pharmacoepidemiology and Drug Safety, Course Co-Coordinator
- PHA 5166L: Professional Skills Lab VI
- PHA 5788C: Patient Care VI: Skin and Musculoskeletal Disorders

Mentoring

PhD Committees

Phuong Pham	Committee Chair	Ongoing
Patrick Squires	Committee Chair	Ongoing

Ching-Yu Wang	Committee Chair	Ongoing
Brian Cicali	Committee Co-Chair	Ongoing
Brianna Costales	Committee Member	Ongoing
Karthik Lingineni	Committee Member	Ongoing
Saima Subhani	Committee Member	Ongoing
Chaejin Kim	Committee Member	Ongoing
Xi Wang	Committee Member	Conferred August 2020
Sascha Wegmann	Committee Member	Conferred December 2019
Corey Hayes	Committee Member (external)	Conferred May 2019
Yan Li	Committee Member	Conferred May 2019
Wei Wang	Committee Member	Conferred May 2019

MS Committees

Ching-Yu Wang	Committee Chair	Completed May 2019
Yue Cheng	Committee Chair	Conferred May 2018
Omotola Olasupo	Committee Chair	Conferred December 2017
Ming Chen	Committee Chair	Conferred December 2017

Student Pharmacist Supervised Research

Allison O'Neill	Independent Research	2019
Sebastian Martens	Independent Research	2019-ongoing
Reba Dookhie	Independent Research	2019-ongoing
Aminha Ullah	Independent Research	2019-ongoing
Rachel Rolon	Independent Research	2019-ongoing
Mikyle Kanarev	Independent Research	2019-ongoing
Viktoria Eberherr	Pharmacy Exchange Program	Spring 2020
Kunal Patel	Intensive Summer Research	2017-2019
Wafa Abuhashem	Pharmacy Exchange Program	Spring 2017
John Shapiro	Independent Research	Fall 2017

Post-doctoral and visiting scholars

Amie Goodin, PhD, MPP	Post-doctoral research associate	2017-2018
Tomiko Sunaga, PhD	Visiting Scholar	2019-2020
Kiyon Rhew, PhD	Visiting Scholar	2019

Press coverage

- Paediatric use of low-cost generic programs in the US. Joshua Brown, January 22, 2016. *Generics and Biosimilars Initiative.* https://perma.cc/9RPG-SNZL
- Opioid epidemic's youngest victims are a growing group, new data show. Ryan White, September 29, 2016, Center for Health Journalism. http://perma.cc/Y7CV-68UH
- More U.S. babies born addicted to opiates like heroin. Lisa Rapaport, September, 26, 2016, Reuters Health. http://perma.cc/27YS-543C
- Kentucky has twice the U.S. rate of drug-dependent babies. Laura Ungar, January 14, 2017. Louisville Courier Journal. https://perma.cc/YNT5-W8SV

- Babies with opioid withdrawal might do better outside the ICU. Lisa Rapaport, February 5, 2018. Reuters Health. https://perma.cc/ULS6-YRN7
- DOAC Adherence May Not Depend on Dosing Frequency. David Wild, October 25, 2018. Specialty Pharmacy Continuum. https://perma.cc/VF83-RENQ
- Consider CBD Drug Interaction Potential – An Expert Interview. Batya Swift Yasgur, October 25, 2019. *Monthly Prescribing Reference*. https://perma.cc/37QY-JQGZ
- Cost-effectiveness of generic dabigatran. Joshua Brown and Ching-Yu Wang, July 7, 2020. *Generics and Biosimilars Initiative*. https://perma.cc/GTQ5-CZJG
- Coronavirus treatment drug UF Health helped develop gets emergency FDA approval. Kelly Wiley, May 1, 2020. *News4Jax* (Graham Media Group). https://perma.cc/RL9Q-KLKJ
- This Expert Explained The Real Difference Between Name Brand and Generic Drugs. Krista Torres, July 12, 2020. BuzzFeed. https://perma.cc/RLX3-DTQH